Breckenridge Pharmaceutical Inc, a subsidiary of Towa Pharmaceutical, announced on Thursday that it has received final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Apixaban Tablets (generic for Eliquis).
Towa Pharmaceutical Europe, SL produced the product at its Martorelles, Spain manufacturing facility. According to industry sales data, Eliquis generated annual sales of USD14 billion during the twelve months ending May 2021.
The company has received a license under confidential terms allowing Breckenridge to introduce generic Apixaban Tablets under its ANDA at a later date.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets